GlassScriptPhysician profile
Robert E Hoskins
NPI 1912404666
$929.26
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $823 · 2022: $86.06 · 2023: $20.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $168.05 | 2021-2022 | |
| Novo Nordisk INC | $156.90 | 2021-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $112.43 | 2021 | |
| Pfizer INC. | $80.66 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.69 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $42.53 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $38.86 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.56 | 2021 | |
| Amarin Pharma, INC. | $35.41 | 2021 | |
| Tris Pharma INC | $30.75 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $30.25 | 2021 | |
| Sanofi-Aventis U.S. LLC | $27.38 | 2021 | |
| Corcept Therapeutics | $21.12 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.38 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.86 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $17.40 | 2021 | |
| Paratek Pharmaceuticals, INC. | $12.21 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hoskins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.